Search

Ye E Liu

from Clarksville, MD
Age ~48
Get Report
Also known as:
Yi I Liu, Yurong Liu, Yuanjin Liu, Liang Liu, Rong Liu Yu, Yi Li
Phone and address:
6828 Walnut Creek Ct, Clarksville, MD 21029
Related to:
Lihua Li, 60
Connected to:
Adela Liu, 73Alec X Liu, 39Alpha T Liu, 46Amon Y Liu, 58Andrea Y Liu, 46Anqi Liu, 39Arden K Liu, 64Ba S Liu, 62Bailu Liu, 35Ban Liu, 48

Ye Liu Phones & Addresses

  • 6828 Walnut Creek Ct, Clarksville, MD 21029
  • Jessup, MD
  • Baltimore, MD
  • 9417 Steeple Ct, Laurel, MD 20723 (301) 776-0342
  • 650 Merrick St, Detroit, MI 48202
  • Northville, MI
  • Troy, MI
  • Barrigada, GU

Work

Company: Albany medical center - Albany, NY Nov 2008 Position: Volunteer

Education

School / High School: Hudson Valley community College- Troy, NY 2011 Specialities: Nursing

Skills

perform nursing process • medication adminstration (oral • IV push • IM) • NG tube flush • dressing change • contact • isolation and standard precaution.

Resumes

Resumes

Ye Liu Photo 1

Accounts Receivable Intern At Fairfax Water

View page
Location:
Washington D.C. Metro Area
Industry:
Accounting
Ye Liu Photo 2

Architect At Tsao & Mckown Architects

View page
Position:
Architect at Tsao & McKown Architects
Location:
New York, New York
Industry:
Architecture & Planning
Work:
Tsao & McKown Architects - New York, New York since Sep 2012
Architect
RTKL Associates Inc. - Washington D.C. Metro Area Jul 2011 - Aug 2012
Architectural and Urban Designer
Atelier Liu Yuyang Architects - Shanghai, China Dec 2007 - May 2009
Senior Project Designer
Fake Design - Ai Weiwei's Studio - Beijing, China Sep 2005 - Aug 2007
Architect & Art Manager Assistant
Arata Isozaki & Associates - Shanghai, China Apr 2006 - Mar 2007
Architect
Education:
Cranbrook Academy of Art 2009 - 2011
Master, Architecture Tongji University 2001 - 2006
Bachelor, Architecture
Skills:
AutoCAD Architecture
Rhinoceros
SketchUp
3ds Max
Adobe Photoshop
Adobe Illustrator
Adobe InDesign
Adobe Dreamweaver
MS-Office
Mac OS X
Windows
Urban Planning
Architecture
Urban Design
Concept Design
Design Development
Modeling
Adobe Creative Suite
AutoCAD
Sketching
Photography
Design Research
Languages:
Chinese
English
Ye Liu Photo 3

Ye Liu

View page
Ye Liu Photo 4

Ye Liu

View page
Ye Liu Photo 5

Ye Liu

View page
Ye Liu Photo 6

Ye Liu

View page
Ye Liu Photo 7

Ye Liu

View page
Ye Liu Photo 8

Ye Liu Loudonville, NY

View page
Work:
Albany Medical Center
Albany, NY
Nov 2008 to Mar 2009
Volunteer
Shenda Trading LLC
Troy, MI
Mar 2006 to Mar 2008
Owner
Ningbo Tianheng Medicine Mfg Inc

Mar 2003 to Feb 2006
Regional Sale Manager
Henan 3rd People Hospital
Zhengzhou, CN
Jul 1998 to Mar 2003
OB/GYN Physician
Education:
Hudson Valley community College
Troy, NY
2011 to 2013
Nursing
Zhengzhou University
Zhengzhou, Henan, China
1993 to 1998
Doctor of Medicine in Clinical medicine
Skills:
perform nursing process, medication adminstration (oral, IV push, IM), NG tube flush, dressing change, contact,isolation and standard precaution.

Publications

Us Patents

Modified Rsv F Proteins And Methods Of Their Use

View page
US Patent:
20100239617, Sep 23, 2010
Filed:
Dec 9, 2009
Appl. No.:
12/633995
Inventors:
Peter PUSHKO - Frederick MD, US
Yingyun Wu - Gaithersburg MD, US
Michael Massare - Mt. Airy MD, US
Ye Liu - Laurel MD, US
Gale Smith - Gaithersburg MD, US
Bin Zhou - Gaithersburg MD, US
International Classification:
A61K 39/155
C07K 14/135
C07H 21/02
C12N 5/10
C12N 7/00
A61K 9/00
A61P 31/14
US Classification:
424400, 530350, 536 234, 435348, 4241861, 4352351
Abstract:
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.

Recombinant Nanoparticle Rsv F Vaccine For Respiratory Syncytial Virus

View page
US Patent:
20130122032, May 16, 2013
Filed:
Sep 27, 2012
Appl. No.:
13/629107
Inventors:
Gale SMITH - Rockville MD, US
Yingyun Wu - Rockville MD, US
Michael Massare - Rockville MD, US
Ye Liu - Rockville MD, US
International Classification:
C07K 14/135
A61K 39/155
US Classification:
4241861
Abstract:
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.

Vaccine Compositions Having Improved Stability And Immunogenicity

View page
US Patent:
20220387579, Dec 8, 2022
Filed:
May 23, 2022
Appl. No.:
17/750612
Inventors:
- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Erica SHANE - McLean VA, US
Cynthia OLIVER - Potomac MD, US
Gregory GLENN - Poolesville MD, US
International Classification:
A61K 39/155
A61K 39/12
A61K 9/00
A61K 9/16
C12N 7/00
Abstract:
Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Methods And Compositions For Inducing Immune Responses Against Clostridium Difficile

View page
US Patent:
20220211834, Jul 7, 2022
Filed:
Aug 10, 2021
Appl. No.:
17/398610
Inventors:
- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Gale SMITH - Germantown MD, US
Gregory GLENN - Poolesville MD, US
David FLYER - Olney MD, US
International Classification:
A61K 39/116
A61K 39/39
Abstract:
Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

Fully-Human Post-Translationally Modified Antibody Therapeutics

View page
US Patent:
20220195462, Jun 23, 2022
Filed:
Apr 24, 2020
Appl. No.:
17/605486
Inventors:
- Rockville MD, US
Zuchun Wu - North Potomac MD, US
Ye Liu - Clarksville MD, US
Sherri Van Everen - Menlo Park CA, US
Franz Gerner - Myersville MD, US
Joseph Bruder - Gaithersburg MD, US
Chunping Qiao - Rockville MD, US
Devin McDougald - Boston MA, US
Xu Wang - Falls Church VA, US
Justin Glenn - Rockville MD, US
International Classification:
C12N 15/86
A61P 17/00
C07K 16/40
Abstract:
Provided are methods and compositions for the delivery of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human post-translationally modified therapeutic monoclonal antibodies may be delivered by gene therapy methods, e.g., as a recombinant adeno-associated vims (rAAV) vector to the appropriate tissue. Methods of manufacture of the AAV vectors, pharmaceutical compositions and methods of treatment are also provided. In addition, provided are methods of producing therapeutic antibodies that are “biobetters” as fully human post-translationally modified. These fully human post-translationally modified therapeutic antibodies may be administered to a subject in need of treatment with the therapeutic antibody.

Recombinant Adeno-Associated Viruses And Uses Thereof

View page
US Patent:
20220186256, Jun 16, 2022
Filed:
Apr 2, 2020
Appl. No.:
17/600418
Inventors:
- Rockville MD, US
Ye Liu - Clarksville MD, US
Andrew Mercer - Poolesville MD, US
Samantha Yost - Rockville MD, US
Elad Firnberg - Baltimore MD, US
International Classification:
C12N 15/86
C07K 14/005
Abstract:
The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences that confer and/or enhance desired properties. In particular, the invention provides engineered capsid proteins comprising peptide insertions from heterologous proteins inserted within or near variable region IV (VR-IV) of the virus capsid, such that the insertion is surface exposed on the AAV particle. The invention also provides capsid proteins that direct rAAVs to target tissues, in particular, capsid proteins comprising peptides derived from erythropoietin or dynein that are inserted into surface-exposed variable regions and that target rAAVs to retinal tissue and/or neural tissue, including the central nervous system, and deliver therapeutics for treating neurological and/or eye disorders.

Methods And Compositions For Treating Respiratory Disease

View page
US Patent:
20210137845, May 13, 2021
Filed:
Jul 24, 2018
Appl. No.:
16/629859
Inventors:
- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Gregory GLENN - Poolesville MD, US
Louis FRIES - Ellicott City MD, US
Iksung CHO - Potomac MD, US
International Classification:
A61K 9/51
A61K 39/155
A61P 31/14
A61P 11/00
Abstract:
Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Vaccine Compositions Having Improved Stability And Immunogenicity

View page
US Patent:
20200101151, Apr 2, 2020
Filed:
Aug 20, 2019
Appl. No.:
16/545424
Inventors:
- Gaithersburg MD, US
Ye LIU - Clarksville MD, US
Jing-Hui TIAN - Germantown MD, US
Michael J. MASSARE - Mt. Airy MD, US
Sarathi BODDAPATI - Germantown MD, US
Erica SHANE - McLean VA, US
Cynthia OLIVER - Potomac MD, US
Gregory GLENN - Potomac MD, US
International Classification:
A61K 39/155
A61K 39/12
A61K 9/00
A61K 9/16
C12N 7/00
Abstract:
Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Control profile
Ye E Liu from Clarksville, MD, age ~48 Get Report